CIK 0001750284
- Non-accelerated filer
- Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 300409740
- Phone
- +1 415-651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-15 | Kovacs Shane William Charles Ch. Operating & Financial Off. | Grant or award | +358,680 | 358,680 | ||
| 2020-06-15 | Harmon Cyrus Chief Technology Officer | Grant or award | +143,472 | 1,040,172 | ||
| 2020-06-10 | Horn Kinney Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +252,060 | 252,060 | ||
| 2020-06-01 | Graham G. Walmsley Director | Purchase · Series B Convertible Preferred Stock | +339,578 | $4.71 | $1.6M | 1,400,761 |
| 2020-06-01 | Graham G. Walmsley Director | Purchase · Series B Convertible Preferred Stock | +339,578 | $4.71 | $1.6M | 339,578 |
Page 24 of 24 · 465 trades